key: cord-0702653-j4irr16r
authors: Yang, Penglei; Wang, Jing; Zheng, Ruiqiang; Tan, Rui; Li, Xianghui; Liu, Xiaoyun; Li, Yang; Yuan, Zhenzhen; Wang, Yue; Chen, Qihong; Yu, Jiangquan
title: Convalescent plasma transfusion therapy in severe and critical COVID-19 patients: A Systematic Review and Meta-Analysis
date: 2022-02-01
journal: Heart Lung
DOI: 10.1016/j.hrtlng.2022.01.019
sha: 33c7b7fbb428eec073d62e57c2d363d5566dd1e6
doc_id: 702653
cord_uid: j4irr16r

BACKGROUND: Convalescent plasma treatment for severe and critically ill Corona Virus Disease 2019 (COVID-19) patients remains controversial. OBJECTIVE: To evaluate the clinical improvement and mortality risk of convalescent plasma treatment in patients with severe and critically ill COVID-19 patients. METHODS: A literature search was conducted in the electronic databases for the randomized controlled studies about convalescent plasma therapy in severe and critically ill COVID-19 patients. Two reviewers independently extracted relevant data. The primary outcomes were clinical improvement and mortality risk of severe and critically ill COVID-19 patients that were therapied by convalescent plasma. RESULTS: A total of 14 randomized controlled trials with 4543 patients were included in this meta-analysis. Compared to control, no significant difference was observed for either clinical improvement (6 studies, RR 1.07, 95% CI 0.97 to 1.17, p = 0.16, moderate certainty) or mortality risk (14 studies, RR 0.94, 95% CI 0.85 to 1.03, p= 0.18, low certainty) in patients of convalescent plasma therapy group. CONCLUSION: Convalescent plasma did not increase the clinical improvement or reduce the mortality risk in the severe and critically ill COVID-19 patients.

Introduction COVID-19 infections are highly contagious, from December 2019 to February 2021, infected more than one hundred million people with almost 2 million deaths in 210 countries [1] . In addition, the Epidemiology Working Group for NCIP Epidemic Response reported, 14% of patients would develop severe infections and suffer severe progressive pneumonia with multiple organ failure [2, 3] . Unfortunately, there is still a lack of effective treatment for the COVID-19.

There are three phases involved in the progression of COVID-19. During the first phase, the virus replicates exponentially to cause tissue damage. In the second phase, the patients present with a hyper-inflammatory reaction, whereas in the third phase, the patient undergoes organ dysfunction and death [4] . Convalescent plasma was collected from the recovered individuals of COVID-19 infections [5] . Convalescent plasma can inhibit viral replication and regulate inflammation, thereby improving the prognosis of patients [6, 7] . Some systematic reviews reported a reduction in the risk of death in patients with severe COVID-19 disease after convalescent plasma treatment [8, 9] . However, these systematic reviews included observational studies or did not set clear diagnostic criteria for patients with severe infection. At the same time, several recent RCT studies have reported that convalescent plasma does not significantly improve prognosis in patients with severe COVID-19 disease [7, [10] [11] [12] . Therefore use of convalescent plasma for the severe COVID-19 infection treatment remains controversial [2, 13] .

We aimed to perform a systematic review and meta-analysis to evaluate the efficacy of convalescent plasma therapy in patients with severe and critically ill COVID-19 patients.

The project was registered on the PROSPERO (CRD42021274365). We performed the meta-analysis and systematic review of the convalescent plasma transfusion therapy in severe and critically ill COVID-19 patients.

From inception till October 18, 2021, we conducted a thorough literature search in the following databases: PubMed, Cochrane Library, Web of Science, EMBASE. Besides, citations of previously published systematic reviews were also searched.

The studies were searched using the keywords such as "COVID-19", "severe acute respiratory syndrome coronavirus 2", "2019-nCoV", "SARS-CoV-2", "coronavirus" "convalescent plasma," "convalescent serum," "Plasma immunoglobulins," and so on. Table S1 shows the detailed search process.

Randomized controlled studies on convalescent plasma to treat severe and critically ill COVID-19 patients were included in this meta-analysis. However, prospective observational studies, retrospective studies, case reports, case series, and retrospective studies were excluded. Additionally, studies in which outcomes could not be extracted, studies containing many incomplete data, and/or duplicate studies were also excluded.

(1) Patients with confirmed SARS-CoV-2 infection by polymerase chain reaction (PCR) testing. There was no limitation of the PCR testing methods.

(2) Pneumonia confirmed by chest imaging. (4) Severe COVID-19 Respiratory distress (RR ≥ 30 breaths/min; resting-state oxygen saturation ≤ 94% on room air and requiring oxygen supplement; or arterial (PaO2)/ (FiO2) ≤ 300mmHg). Critical respiratory failure requiring mechanical ventilation, shock, or other organ failures (apart from the lung); requires monitoring intensive care unit (ICU) [2, 13] .

(1) Pregnancy or lactation (2) Blood component allergies

Two independent reviewers (Yang and Wang) performed a literature search and screening. In the case of inconsistencies in the data screening and extraction process, the conflicts were resolved using a group discussion and consultation with Professor Zheng RQ, a highly qualified COVID-19 treatment specialist. First, reviewers screened the literature titles and assessed the entire manuscript. Duplicate references were eliminated. After that, the following information was extracted from the studies: clinical improvement rate, mortality rate,72h, 7th-day nucleic acid negative rate, oxygen support time, hospitalization, and discharge time. If there were several time points for clinical improvement, mortality, and discharge rate, we extracted the day closest to 28-day data. However, if data of 28-day could not be extracted, the data of 30-, 60-and 90-days were included in the analysis. At the same time, the patient's basic information was detracted: age, male, symptom onset to randomization, plasma usage control method, Plasma antibody titer, post-treatment patient antibody titer, etc.

Finally, the data was converted to mean and standard deviation if reported as the median and interquartile range (IQR) for continuous variables [14, 15] .

Primary outcomes: symptoms improvement and mortality rate. Secondary outcomes: 3-day and 7-day nucleic acid conversion rate, oxygen support duration, hospital stay duration, discharge rate.

All studies were assessed for risk of bias (RoB) using the Risk of Bias 2 (RoB2) tool [16] . Risks were classified as low, high, and unknown. Besides, a GRADE (Grading of Recommendations Assessment Development and Evaluation) evaluation was also performed [17] . However, more than five trials are required to study the outcomes to avoid the risk of publication biases. Therefore, we used funnel charts and Egger's test for published bias testing.

Two researchers carried out the data analysis. Mantel-Haenszel statistics and inverse variance models were used for the meta-analysis. Outcome data were analyzed by the Review Manager 5.3. The inverse variance model assessed the study weights.

Relative risk was calculated for the result of dichotomous variables such as mortality.

The mean, standard deviation (SD), and 95% confidence intervals (CI) for continuous variables were calculated. The χ2 test, I 2 , was used to evaluate the homogeneity, where I 2 ≥50% represented high heterogeneity. For data with high heterogeneity, a random model was used. For the primary mortality outcomes, sequential research was conducted to evaluate if the sample size of the results was sufficient. In the trial sequential analysis (TSA), the required information size was based on a type I error of 5%, a beta of 20%, the proportion of participants in the control group with the outcome, and a relative risk reduction of 15% and 30%.

Li et al. reported that convalescent plasma therapy was effective for severely infected, but not for critically ill patients 2 . Therefore, we performed the subgroup analysis for severe and critically ill patients for clinical improvement and mortality. Besides, to resolve the controversy regarding the literature about convalescent plasma therapy for patients with severe COVID-19 infection, we performed a sensitivity analysis to assess the consistency of the results.

A total of 834 articles were retrieved. Only 830 studies had electronic data on PubMed, Embase, Web of SCI, and Cochrane Library, whereas 5 papers were retrieved in a previously published meta-analysis [18] [19] [20] [21] [22] . After that, 798 records were further processed after the removal of duplicates. After thoroughly reading the title and the abstract, unrelated literature on the convalescent plasma treatment of COVID-19 was excluded. After scrutinizing the studies based on the inclusion & exclusion criteria, a total of 14 randomized controlled trials and 4543 patients were included in the meta-analysis [2, 7, [10] [11] [12] [13] [18] [19] [20] [21] [22] [23] [24] [25] (Fig.1) .

The included studies were conducted in China [2] , India [21, 23] , Argentina [11] , Bahrain [19] , Iraq [18, 20] , the United States [25] , Germany [24] , and Brazil [12, 13] , Iran [7] , Netherlands [10] , Only 4 studies were on severe COVID-19 patients [11, 21, 23, 25] , whereas ten studies included both the severe and critically ill COVID-19 patients [2, 7, 10, 12, 13, 18-20, 22, 24] . Data of severe and critical patients were extracted separately in three trials [2, 10, 13] . Convalescent plasma therapy was compared to the standard treatment in twelve studies [2, 7, 10-12, 18, 19, 21-25] . In two trials, convalescent plasma was compared to the control plasma [13, 20] . Anti-SARS-CoV-2 antibody titers were tested in all studies [2, 7, [10] [11] [12] [13] [18] [19] [20] [21] [22] [23] [24] [25] . Characteristics of the included studies are shown in Table 1 . Table S2 shows the certainty of the obtained results.

Compared to patients of control group, no significant difference in clinical improvement (6 studies, RR 1.07, 95% CI 0.97 to 1.17, p = 0.16, moderate certainty) ( Fig. 3a) and mortality risk (14 studies, RR 0.94, 95% CI 0.85 to 1.03, p = 0.18, low certainty) (Fig. 4a) was observed for patients of convalescent plasma therapy group.

There was no publication bias found in the clinical improvement (Egger's test, p = 0.154) (Fig.4b) , but a publication bias was observed in the mortality risk (Egger's test,

We performed a sequential analysis for the mortality rate. A total of 4543 patients were included in our study, with an actual sample size of 4290 patients (Fig. 5) . Outcome estimates were based on the following statistical indicators: the probability of type I error (α = 0.05), probability of type II error (b = 0.2), relative risk reduction (RRR = 30%), and 15% event rate in the control group. The TSA results showed that the cumulative Z value neither crossed the traditional cut-off nor the TSA cut-off nor reached the required patient sample size.

The Agarwal A, O'Donnell MR, reported the duration of respiratory support [13, 23] , however, data on the time of respiratory support could not be converted to mean and SD. Therefore, we could not conduct a meta-analysis on the respiratory support timing. Compared to the control, time of respiratory support of convalescent plasma group patients was in concurrence with the findings of Agarwal A (median 9 days, IQR: 6 to 13 vs. 10 days, IQR:6 to 13, p = 0.7) and O'Donnell MR (median 6 days, IQR: 3 to 16 vs. 7 days, IQR:3 to 11, p = 0.508) [13, 23] . In addition, the studies by Sekine L et al. (median 11 days, minimum 0 days, maximum 21 days vs. median 7.5 days, minimum 0 days, maximum 22 days, p = 0.444) [12] and the REMAP-CAP investigators(OR 0.95, 95% CI 0.81 to 1.11, p > 0.05) [22] , reported that patients in the convalescent plasma treatment group and control patients had no significant difference in the period without respiratory support.

Eeven trials reported the time to hospital discharge [2, 7, [11] [12] [13] [19] [20] [21] [22] [23] [24] , however, the time to hospital discharge data could not be detracted, and no difference in time to hospital discharge was observed between patients in the convalescent plasma treatment with the control group (p>0.05) [2, 11, 13, 21, 22, 24] . Furthermore, the meta-analysis showed no differences in time to hospital discharge between patients in the convalescent plasma treatment and the control group (5 studies, MD -1.02 days, 95% CI -3.76 to 1.72, p = 0.47, very low certainty) (Fig. S1 ).

Three trials reported negative nucleic acid rates at 72h and 7 days for COVID-19 [2, 12, 23] . Two trials reported the rate of COVID-19 nucleic acid negative within 72h [2, 23] .

Two trials reported COVID-19 nucleic acid negative rates within the 7 days [12, 23] . However, no difference in COVID-19 nucleic acid negative rate at 72h (2 studies, RR 1.62, 95% CI 0.83 to 3.16, p = 0.16, very low certainty) and 7 days (2 studies, RR 1.19, 95% CI 1.00 to 1.40, p = 0.05, low certainty) between convalescent plasma therapy and control group patients (Fig. S2 & S3) .

Five trials reported discharge rates [2, [11] [12] [13] 24] , however, no significant difference was observed in the discharge rate between patients in the convalescent plasma therapy and those in the control group (Five studies, RR 1.08, 95% CI 0.98 to 1.19, p = 0.14, moderate certainty) (Fig. S4 ).

We performed a subgroup analysis to investigate the effect of convalescent plasma therapy on clinical improvement and mortality rate in severe and critically ill COVID-19 patients. In the critically ill COVID-19 patients, convalescent plasma did not increase the rate of clinical improvement (two trials, RR 0.97, 95% CI 0.49 to 1.92, p = 0.93, very low certainty) or decrease the mortality risk (three trials, RR 0.65, 95% CI 0.38 to 1.12, p = 0.12, very low certainty) (Fig. 3 & 4) . Similarly, in severe COVID-19 patients, convalescent plasma did not increase the rate of clinical improvement (Four trials, RR 1.06, 95% CI 0.96 to 1.17, p = 0.25, moderate certainty) or reduce the mortality risk (seven trials, RR 0.93, 95% CI 0.76 to 1.13, p = 0.46, moderate certainty) (Fig. 3 & 4) . Of note, there was a publication bias in the mortality risk parameter (Egger's test, p = 0.07) (Fig. 4) .

There was a conflict for patients with severe COVID-19 infection in studies of Bégin P [25] and Agarwal A [23] . Therefore, a sensitivity analysis was performed to exclude studies of Bégin P [25] and Agarwal A [23] . However, the sensitivity analysis did not reveal any significant difference in mortality risk (12 studies, RR 0.92, 95% CI 0.83 to 1.02, p = 0.10, low certainty) (Fig. S5) between patients of the convalescent plasma therapy and standard treatment group. Moreover, there was a publication bias in the mortality risk parameter (Egger's test, p < 0.001). In the critically ill COVID-19 patients, convalescent plasma did not decrease the mortality risk (three trials, RR 0.65, 95% CI 0.38 to 1.12, p = 0.12, very low certainty) (Fig S5) . Similarly, in severe COVID-19 patients, convalescent plasma did not reduce the mortality risk (five trials, RR 0.72, 95% CI 0.51 to 1.04, p = 0.08, moderate certainty) (Fig S5) .

Our study observed that convalescent plasma treatment for patients with severe and critically ill covid-19 infection could not increase the rate of symptomatic improvement or reduce the risk of death. Meanwhile, the convalescent plasma could not reduce the length of stay in the hospital or the time of oxygen support. Moreover, convalescent plasma did not significantly affect the 72h nucleic acid conversion rate and 30-day discharge rate. However, the therapy increased the 7-day nucleic acid conversion rate, though the increase was not statistically significant. COVID-19 is a highly infectious disease with a high risk of death [26] , as the virus can invade multiple organs, causing acute respiratory distress syndrome, infectious shock, and multiple organ failure [27] . The lungs are the typical target organ. Besides, studies have reported a positive correlation between the severity of lung infections with the respiratory viral load [28] . Convalescent plasma reduces the viral infection rate by binding to the virus and removing pathogens through various pathways, such as complement activation and phagocytosis [29] . Moreover, in patients presenting with mild disease, early administration of convalescent plasma (within 3 days) significantly reduces the risk of progression to severe infection [30] and the risk of death [4] . However, a recent meta-analysis on mild, moderate, severe, and critically infected patients revealed that the convalescent plasma did not reduce mortality [31] . patients, where 150 were randomized to receive convalescent plasma and 73 to receive normal control plasma. The study found that the convalescent plasma did not improve clinical symptoms but reduced the risk of death in patients with severe infections [13] . Another meta-analysis including observational and retrospective studies concluded that convalescent plasma therapy reduces the risk of death in patients with severe infections [34, 35] . However, recent RCT studies have shown that the use of convalescent plasma did not improve the prognosis of patients with severe disease [11, 12, 19, 24, 25] . Meanwhile, a study found that convalescent plasma had variable results in improving patient's clinical symptoms between severe and critical infections. Notably, the study showed that the treatment with convalescent plasma showed an increased clinical improvement in patients with severe COVID-19 (p < 0.1) [2] . In the meta-analysis, with subgroup analyses of severe and critically ill COVID-19 patients, convalescent plasma could decrease the mortality rate in severe COVID-19 patients [36] , however, the data was majorly extracted from the observational research [36] . The recent meta-analysis of Cao et al. also found that the convalescent plasma could decrease the mortality rate for severe or critical patients [37] . The meta-analysis results of Cao et al. [37] differ from our study, as they only analyzed 28-days mortality data.

Still, most studies [7, 10, 11, 18, 22, 24, 25] reported a risk of death at 30-, 35-, 60-, and 90-days were not included in the analysis. Meanwhile, the meta-analysis of Cao et al.

[37] did not define the diagnostic criteria for severe COVID-19 infection; thus, these two studies could not be included in the analysis. Of note, the sensitivity analysis showed that the convalescent plasma could not reduce the mortality risk, even though the studies of Agarwal A [23] and Bégin P [25] were excluded from the analysis. These results were similar to the study by Min et al., in which the subgroup of the RCT convalescent plasma did not reduce the mortality risk of patients with moderate and severe infections [2] .

Our study found that convalescent plasma in severe or critically ill patients did not improve the clinical symptoms or reduce the death risk. Our results concur with Gupta et al., [31] and Janiaud et al., [38] . However, we included only severe and critically ill patients for subgroup analyses. Of note, our study found that the convalescent plasma could increase the 7day nucleic acid conversion rate; however, the increase was not statistically significant. The observation needs to be validated further in a large sample size study.

This study had the following limitations：1. We did not consider 

AlQahtani Table 1 Characteristics of included studies. The funnel graph of mortality risk.

Results of sequential analysis of mortality. TSA, trial sequential analysis.

COVID-19 in early 2021: current status and looking forward

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China

Effect of time and titer in convalescent plasma therapy for COVID-19. iScience 2021

Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow

Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes

A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm

Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis

Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial

A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19

Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Risk on bias assessment: (2) Revised Cochrane risk of bias tool for individually randomized, parallel group trials (RoB2.0). Zhonghua liuxingbingxue zazhi

Making GRADE accessible: a proposal for graphic display of evidence quality assessments

The therapeutic potential of Convalescent COVID-19: an open-label, randomized controlled trial

Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city

Repositioned Drugs for COVID-19-the Impact on Multiple Organs

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

Systematic review and meta-analysis of randomised

The authors would like to thank all the reviewers who participated in the review and MJEditor (www.mjeditor.com) for their linguistic assistance in preparing this manuscript.